Products and
Pipeline

Overview^1-2

TAK-940 is an autologous next-generation CAR-T with modified ITAM (intracellular tyrosine based activation motif) signaling

MOA²

- TAK-940 (or autologous anti-CD19 CAR T cells 19(T2)28z1xx), is a collaboration with MSKCC. The product consists of autologous T cells that have been genetically modified to express a CAR targeting the tumor associated antigen (TAA) CD19, linked to the costimulatory intracellular signaling domains of CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) (CD28zeta; CD28z), with potential immunostimulating and antineoplastic activities

- Anti-CD19 CAR T cells 19(T2)28z1xx specifically recognize and bind to CD19-expressing tumor cells (expressed in B cell lineage malignancies), resulting in T cell-mediated tumor cell lysis

- CD28 and CD3zeta provide co-stimulatory activity and may enhance the cytotoxic effect and anti-tumor activity of CAR T cells

- The 19(T2)28z1xx CAR T cells include a 1928zeta mutant, 1xx, which contains one instead of all three immunoreceptor tyrosine-based activation motifs. This characteristic may help prevent counterproductive T cell differentiation and exhaustion

MSKCC = Memorial Sloan Kettering Cancer Center

Clinical Trials

Study Name

A Phase I Study of CD19-Targeted 19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells in Adult Patients With Relapsed or Refractory
B-cell Malignancies

References

1. Feucht J, et al. Nat Med. 2019;25:82-88.

2. Takeda, Data on file.

Disclaimers

*In collaboration with Memorial Sloan Kettering Cancer Center.